On this page

Zenalpha®

Medetomidine hydrochloride Vatinoxan hydrochloride

Veterinary NADA Approved 2,623 adverse event reports

Overview

Source: Animal Drugs @ FDA
Proprietary name
Zenalpha®
Active ingredient
Medetomidine hydrochloride Vatinoxan hydrochloride
Application type
NADA
Sponsor
Dechra Veterinary Products LLC
Applications on record
1
First published
July 14, 2026

Adverse event reports

Source: openFDA VeDDRA
2,623
Reports mentioning this ingredient
October 11, 1996 – January 5, 2026
71
Classified serious
per reporter assessment
38
Lack of expected efficacy
resistance signal
33
Human operator exposure
needle-stick or splash
Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “MEDETOMIDINE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term) Reports Relative frequency
INEFFECTIVE, SEDATION 685
Death 464
Sedation prolonged 215
Vomiting 187
Cardiac arrest 174
Bradycardia 167
Apnoea 154
Depression 145
Convulsion 141
Anorexia 124
Labelled drug-drug interaction medication error 122
Hypersalivation 89
Lung oedema 86
Fever 85
Cyanosis 83
Dyspnoea 79
Elevated alanine aminotransferase (ALT) 76
Death by euthanasia 68
Elevated serum alkaline phosphatase (SAP) 67
Ataxia 66

Species affected

Source: openFDA VeDDRA
Dog 2,090 Cat 463 Human 19 Other 10 Rabbit 4 Monkey 4 Rat 3 Horse 2 Pig 2 Other Deer 2 Deer 2 Tiger 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA FDA CVM Applications, sponsor, status, withdrawal
Animal & Veterinary Events FDA CVM VeDDRA adverse event aggregates by active ingredient